Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease

Ruben Y Gabriëls, Anne M van der Waaij, Matthijs D Linssen, Michael Dobosz, Pia Volkmer, Sumreen Jalal, Dominic Robinson, Marcela A Hermoso, Marjolijn N Lub-de Hooge, Eleonora A M Festen, Gursah Kats-Ugurlu, Gerard Dijkstra, Wouter B Nagengast*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

2 Citaten (Scopus)
7 Downloads (Pure)

Samenvatting

OBJECTIVE: Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using fluorescence molecular imaging (FMI).

DESIGN: Forty three FMI procedures were performed, which consisted of macroscopic in vivo assessment during endoscopy, followed by macroscopic and microscopic ex vivo imaging. In phase A, patients received an intravenous dose of 4.5 mg, 15 mg vedo-800CW or no tracer prior to endoscopy. In phase B, patients received 15 mg vedo-800CW preceded by an unlabelled (sub)therapeutic dose of vedolizumab.

RESULTS: FMI quantification showed a dose-dependent increase in vedo-800CW fluorescence intensity in inflamed tissues, with 15 mg (153.7 au (132.3-163.7)) as the most suitable tracer dose compared with 4.5 mg (55.3 au (33.6-78.2)) (p=0.0002). Moreover, the fluorescence signal decreased by 61% when vedo-800CW was administered after a therapeutic dose of unlabelled vedolizumab, suggesting target saturation in the inflamed tissue. Fluorescence microscopy and immunostaining showed that vedolizumab penetrated the inflamed mucosa and was associated with several immune cell types, most prominently with plasma cells.

CONCLUSION: These results indicate the potential of FMI to determine the local distribution of drugs in the inflamed target tissue and identify drug target cells, providing new insights into targeted agents for their use in IBD.

TRIAL REGISTRATION NUMBER: NCT04112212.

Originele taal-2English
TijdschriftGut
DOI's
StatusE-pub ahead of print - 5-apr.-2024

Vingerafdruk

Duik in de onderzoeksthema's van 'Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease'. Samen vormen ze een unieke vingerafdruk.

Citeer dit